Merck paper was subjected to extensive scrutiny by UBS AG analyst Matthew Weston.
The major Swiss bank UBS has left the rating for Merck KGaA at “Buy” with a price target of 150 euros. The Darmstadt-based company’s outlook is confusingly adjusted for Mavenclad sales in the USA from March and the US potential of Pergoveris, wrote Matthew Weston on Thursday. Therefore, it may seem a bit weak at first glance, but according to the company’s definition it is roughly in line with its expectations.
Between price and quarter: This is what Merck shares are doing on the day of the detailed examination
Shareholders sent Merck shares down. In the XETRA session at 11:18 a.m. the share lost 1.2 percent to EUR 121.55. As a result, the stock still has an upside potential of 23.41 percent based on the price target. The trading volume most recently amounted to 183,619 Merck shares. Looking ahead to 2026, the share fell by 0.9 percent.
ZURICH (dpa-AFX Analyzer) / editorial team finanzen.net
Original study published: March 5, 2026 / 07:20 / GMT
First distribution of the original study: March 5, 2026 / 07:20 / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 Para. 1 WpHG, Art. 20 Regulation (EU) 596/2014 for the analyst firm mentioned can be found at http://web.dpa-afx.de/offenlegenspflicht/offenlegens_pflicht.html.
Selected leverage products on Merck
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Merck
The leverage must be between 2 and 20
Advertising
